Latest news
Stay in the know about our progress, and visit our Newsroom
Combining scientific excellence, financial capacity and dealmaking experience, we believe in the power of strong partnerships to pioneer for patients, together.
Strategic partnership
Galapagos and Gilead have been collaborating since 2015 on the development and, later the commercialization, of filgotinib in inflammatory diseases. The companies expanded their collaboration in 2019 with a 10-year transformative research and development agreement.
Pioneering for patients, together
If you believe your assets fit Galapagos’ strategy or like to learn more about our in-licensing or partnering efforts, please contact our Business Development team.
Please note that any business development proposals that are submitted to Galapagos via email or via our website will be considered non-confidential. No information exchange may be deemed confidential without a signed confidentiality or disclosure agreement from Galapagos.
Stay in the know about our progress, and visit our Newsroom
Looking for information about our company, our stock and our financials?